NLA Endorses Newly Published 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

The NLA, the sole endorser of the new Expect Consensus Decision Pathway document and partner on the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, is excited about the guidance provided by the ACC writing group and the opportunity for the NLA to provide additional direction to its membership and the interested members of the lipid community.